Literature DB >> 18588933

Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.

Daniela M Resende1, Bráulia C Caetano, Míriam S Dutra, Marcus L O Penido, Christiane F Abrantes, Rodrigo M Verly, Jarbas M Resende, Dorila Piló-Veloso, Simone Aparecida Rezende, Oscar Bruna-Romero, Ana Paula Fernandes, Ricardo T Gazzinelli.   

Abstract

A2 was identified as an amastigote virulence factor of Leishmania (Leishmania) donovani and as a candidate antigen for vaccine development against visceral leishmaniasis. Here, predicted hydrophilic, class I and II MHC-binding synthetic peptides were used to define epitopes recognized by A2-specific antibodies, CD8+ T and CD4+ T cells, respectively. Immunization of BALB/c mice with adenovirus expressing A2 (AdA2) resulted in low antibody response, contrasting with high levels of IFN-gamma producing CD4+ T and CD8+ T cells specific for A2. Further, A2-specific CD8+ T cells from immunized mice were capable of lysing sensitized target cells in vivo. Finally, we demonstrated an association of A2-specific T cell responses and reduced parasitism in both liver and spleen from mice immunized with AdA2 and challenged with L. (L.) chagasi.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588933     DOI: 10.1016/j.vaccine.2008.05.091

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Authors:  Leoneide Érica Maduro Bouillet; Mariana Oliveira Dias; Natália Alves Dorigo; Andrew Douglas Moura; Bruce Russell; Francois Nosten; Laurent Renia; Erika Martins Braga; Ricardo Tostes Gazzinelli; Maurício M Rodrigues; Irene S Soares; Oscar Bruna-Romero
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

2.  A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.

Authors:  Bahareh Vakili; Navid Nezafat; Bijan Zare; Nasrollah Erfani; Maryam Akbari; Younes Ghasemi; Mohammad Reza Rahbar; Gholam Reza Hatam
Journal:  Med Microbiol Immunol       Date:  2019-11-06       Impact factor: 3.402

Review 3.  CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly.

Authors:  Fernanda O Novais; Phillip Scott
Journal:  Semin Immunopathol       Date:  2015-03-24       Impact factor: 9.623

4.  MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.

Authors:  Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

Review 5.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

6.  Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients.

Authors:  Inès Lakhal-Naouar; Thouraya Boussoffara; Amel Meddeb-Garnaoui; Yosser Ben Achour-Chenik; Hechmi Louzir; Mehdi Chenik
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

7.  Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis.

Authors:  Maria Marta Figueiredo; Anna R R Dos Santos; Lara C Godoi; Natália S de Castro; Bruno C de Andrade; Sarah A R Sergio; Selma M B Jerônimo; Edward J de Oliveira; Ruth T Valencia-Portillo; Lucilândia M Bezerra; Hiro Goto; Maria C A Sanchez; Caroline Junqueira; Santuza M R Teixeira; Flávio G da Fonseca; Ricardo T Gazzinelli; Ana Paula Fernandes
Journal:  J Immunol Res       Date:  2021-04-28       Impact factor: 4.818

8.  Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; Ricardo De La Fuente; Aldara Herrero-Gil; Lara Ordóñez-Gutiérrez; Javier Carrión
Journal:  Vet Res       Date:  2012-08-09       Impact factor: 3.683

9.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

10.  Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.

Authors:  Vivian T Martins; Miguel A Chávez-Fumagalli; Lourena E Costa; Adriana M C Canavaci; Adriana M C C Martins; Paula S Lage; Daniela P Lage; Mariana C Duarte; Diogo G Valadares; Rubens D M Magalhães; Tatiana G Ribeiro; Ronaldo A P Nagem; Wanderson D Darocha; Wiliam C B Régis; Manuel Soto; Eduardo A F Coelho; Ana Paula Fernandes; Carlos A P Tavares
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.